<DOC>
	<DOC>NCT02277613</DOC>
	<brief_summary>This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).</brief_summary>
	<brief_title>A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Subjects of either gender, 1885 years of age, inclusive Diagnosis of nonST elevation myocardial infarction (NSTEMI) Left Ventricular Ejection Fraction (LVEF) between ≥ 25 and ≤ 45% Previous Coronary Artery Bypass Graft (CABG) Previous autologous, allogeneic bone marrow or peripheral stem cell transplant Previous solid organ transplant Anticipated need for additional planned coronary revascularization procedure(s) Hemodynamic instability Mechanical complications of the index acute myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stem cells</keyword>
</DOC>